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This paper contains a discussion and test of the technology gap approach to the innovation and 
growth in the bio-pharmaceutical industry between industrialized and developing countries (Mexico, 
Korea, India, China, Brazil, Argentina, Ireland) for the period 1980-2005. We find among the 
industrialized countries convergence path with respect to the leader, the United States. But from the 
developing countries, South Korea and Ireland the innovation tends to be systematic and increasing. 
The technological backwardness is more obvious in Mexico and Argentina than in India and Brazil. 
In both block of countries the dynamics in the processes of innovation is explained by the advances in 




The aim of this paper is to examine if there is a convergence process and/or catching up tendency 
across industrialized and developing countries in the context of a high tech industry. We test 
technological convergence across countries in the pharmaceutical industry during the 1980- 2005 
period, using the technological innovational gap approach. Among the questions to be examined in 
this research are the following: Is convergence and catch-up of developing countries with respect to 
industrialized countries possible in a high industry? What are the main factors underlying 
convergence or divergence? 
This research proposes to confirm the hypotheses stated for the focus on technological 
gaps, but at the industry level: the growth divergences of the pharmaceutical sector of the developing 
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countries compared to the industrialized countries are strongly linked to the technology and 
innovation gaps. The catch-up possibilities in this high technology industry for developing countries 
can only be explained with rates of economic growth higher than those registered by industrialized 
countries, linked to an important development of technological and institutional capacities. The 
correlation that is established between R&D and patents contribute to develop the capacity for 
innovation and helps to create a virtuous circle that, joint to technological transfer and productivity 
growth, could lead developing countries along the path to convergence and catch-up. 
The work is presented in three sections. In the first the theoretical discussion of the 
research is presented. In the second the empirical evidence of the technological gaps and the 
tendencies to convergence or divergence of the pharmaceutical industry across countries are 
analyzed. Finally, the conclusions of the work are presented. The methodology and the sources used 
in the research are specified at the end. 
 
I. The Technological Gap Approach 
 
The processes of economic convergence or divergence have been associated, along with other 
factors, with differentials of technological development and human resources (Abramovitz, 1986; 
Maddison, 1982; Baumol, 1986). The technological gap approach developed by Posner (1961), 
Gomulka (1971), Cornwall (1977), Abramovitz (1986) and other authors proposes that the significant 
differentials in the levels and technological tendencies that characterize the international economic 
system will only be overcome with radical transformations in the technological, economic, and social 
structures
1
. Other authors involved in technological catch up theorical discussion are Veblen (1915), 
Nurske (1955), Gerschenkron (1962) and Rostow (1971). The approach assumes the existence of a 
close correlation between the economic and technological level growth rates. The relative 
technological backwardness of the poor countries brings with it an opportunity for their quick 
economic growth (Abramovitz, 1966 y 1986). Indeed, these countries have a great potential because 
of the very fact of their backwardness, to the extent that it is possible for them to imitate the more 
advanced countries and adopt the best techniques
2
. So the imitative strategy would make it possible 
                                                 
1 The works of K. Pavitt and L. Soete have proved the hypotheses presented by M.V.Posner (1961) and S. Gomulka (1971), quoted in J. Fagerberg 
(1987). 
2 B. Amable, R. Barré and R. Boyer  (1997), p. 62. 
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for technologically backward countries, with respect to the global innovation frontier, to increase 
their rate of economic growth. However, the possibilities of convergence and catch-up are 
conditioned by the capacity to transform the social, institutional, and economic structures. The 
existence of infrastructural capabilities (Abramovitz, 1986) and the reform of institutions (Maddison, 
1982) are necessary conditions for rapid economic and catch-up growth.  
 
The neoclassical growth models (starting with Solow, 1959) predict an economic growth long 
run positive rate only if technological change occurs. The recognition of technology progress 
influence, like an exogenous variable, on economic growth, was tested in various empirical 
researches. The new growth models (Romer, 1986, 1990; Lucas, 1988; Barro, 1988, among others) 
point out the accent on knowledge generation, as an endogenous variable; even if the firms produce 
the knowledge, they could be beneficiated from knowledge spillovers coming from the whole 
economy. The technological catch up is defined as “the process by which countries may benefit from 
the existence o a stock of production knowledge available in the rest of the world (that is generally 
called technology gap” (Rogers, 2003: 43). In this context, the explanation of technological dynamics 
differences across countries involves a main question empirical question: “how countries learn and 
absorb technology from the rest of the world?” (Ibid).  
 
Factors that Contribute to Technological Convergence  
When a long period in which the capital to product relation does not change is considered, the 
variation between countries can be explained by innovation.
3
 In that sense, the gap is an aggregate 
indicator of some of the factors that influence the rate of international technology transfer, and hence 
the growth rates of innovation and labor productivity in the technology-importing countries 
(Gomulka, 1990, p. 155). In this way a virtuous circle between capital investment and innovation is 
established. 
 
In the logic of the virtuous circle that is established between capital investment and 
innovation, the investment decisions regarding physical capital and R&D imply a conditionality and 
                                                 
3 Nowadays the innovation process is conceived of as the result of a permanent interaction between the supply of available knowledge, the fruit of 
scientific investigation, and the strategic decisions of the enterprise. 
 
Paper presented in the VI Globelics Conference, September 22-24 2008, Mexico City 
 
 
complementariness in the strategy of the firms in order to compete in the marketplace. In effect, the 
production of a new product derived from R&D often requires the amplification of productive 
capacities or the adaptation of plants, but this in turn requires the support of specialized technological 
studies (Guellec, 1993). 
 
II. The Empirical Evidence. Technological gaps and converging trends in the 
pharmaceutical industry across countries 
 
The nature of the world pharmaceutical industry competitive environment has changed in the 
last three decades associated to three main facts. Firstly, the scientific and technological advances in 
biotechnology and genetic medicine fields have fostered a new technological pharmaceutical 
paradigm (Landau et al., 1999; Morange, 2003). Secondly, the pharmaceutical firms fusions, 
acquisitions and strategic alliances process since the 80s, linked to technological competition and 
the need to join R&D efforts, has favored the drugs market concentration (Weinmann, 2002). 
Thirdly, there has been a globalization tendency where the production is essentially based in the 
large pharmaceutical firms (multinationals) from industrialized countries (where United States has 
an important leadership), but there is an increasing importance in emerging countries like India, 
China, and Brazil as generic drugs producers bound to the investment flows coming from the 
industrialized countries. Even if the R&D has been concentrated in developed countries, some drug 
development and production steps have been placed in developing countries (Eastern Asian, Eastern 
European and Latin American countries) opening them to new productive and knowledge 
opportunities. The bio-pharma R&D activities delocalization are highly associated with the human 
capital levels and capabilities in different countries (commonly, in the developed countries) and low 
researcher wages advantage (specially, in the developing countries) and, boosted by the information 
and communication technologies (ICT) environment.  
 
However, even while technology flows in the pharmaceutical industry occur essentially 
between industrialized countries, some developing countries participate as clinical trial centers, and 
as important producers of generics (OCDE, 2001). In this context, countries such as India and China 
are significant as pharmaceutical exporters to other Asian and African countries and Mexico and 
Brazil in the case of Latin American countries. Coming from an initial production based on an 
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imitation strategy since the postwar era, some developing countries as Korea, India, Taiwan, 
Argentina, Mexico, Brazil, and more recently China, have become important generics producers. 
Nevertheless, some of these developing countries followed a passive strategy regarding 
technological progress, and others, simultaneously strengthened their production of generics and 
oriented themselves toward an active strategy based on R&D and innovation (Zúñiga, Guzmán & 
Brown, 2007). Taking into account the pharmaceutical R&D efforts and the innovation activity of 
each country selected in this study we are now going to identify the countries innovation dynamic 
and to test if a convergence or catching up process across the countries has been occurred. 
 
Technological performance trends in pharmaceutical industry 
 
The technological gaps between industrialized and developing countries are every day more 
evident in industries such as the pharmaceutical, one because of enormous differentials in R&D 
expenditure as a percentage of GDP of the sector and the per capita patents. The divergent tendency 
manifests itself, as has been pointed out earlier, when social capacities are lacking and a low rate of 
technology transference and a reduced per capita GDP are registered. This tendency is accentuated 
with strong intellectual property protection policies, especially in the lengthening of the duration of 
the patents. 
 
The study of technological gaps in the pharmaceutical industry is a long-term analysis during 
the 1980- 2005 period. Two blocs of countries are considered. The first one concerns the 
industrialized countries, characterized by a sophisticated pharmaceutical industry, with significant 
R&D expenditures, a relative homogeneity in the strength intellectual property systems and a 
significant patenting activity (The United States, Japan, Canada, Germany, France, the United 
Kingdom, Belgium, Denmark, Spain, Finland, Netherlands, Norway and Australia). The second 
refers the developing countries, identified as countries with strong imitative capabilities, 
differentiated levels of GDP per capita, R&D, and intellectual property rules and each one has 
introduced at least one new molecule (Mexico, Korea, India, China, Brazil, Argentina, Ireland). 
We have estimated three technological indicators measured as average and with a coefficient 
variation in three different periods (1980-1990; 1991-2000 and 2001-2005) to identify the 
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pharmaceutical innovation capabilities and trend of each country selected.
4
 Firstly, we have 
calculated the pharmaceutical inventive capacity performance based on the USPTO patents per one 
hundred thousand inhabitants and weighted by exportation’s country. Secondly, we have estimated 
the pharmaceutical innovation productivity level (bio-pharmaceutical USPTO patents per number of 
employees engaged
5
). Thirdly, the pharmaceutical R&D effort (pharmaceutical R&D expenditure as 
a percentage of the pharmaceutical value added) is considered as the innovation’s inputs of each 
country.  
 
According to our estimations of the pharmaceutical inventive capacity countries 
performance, based on the patents, weighted by its population and the export coefficient, we point 
out the following:  
 
Among industrialized countries there are different innovative paths. In which concern to 
the patents weighted by the size of the country, Japan stands out as that one which has the higher 
level on inventive capacity during the two sub-periods, but in the last one has registered a big 
slowdown. This high indicator of inventive capacity of Japan could be explained because the 
pharmaceutical export coefficient is very little and therefore the relative measure of patents is high.  
United States maintains an extensive leadership in pharmaceutical inventive activity over the other 
industrialized countries during the whole period studied, even if the index is relatively low 
compared to Japan in the two first periods. It is suitable to underline the significant increase that 
United States has registered in the second period, during the nineties when most of countries, 
adhered to OMC, have strengthened the intellectual property in the framework TRIPS’s adoption, 
that was designed to discourage imitation in other countries. A similar path could see with the case 
of Canada. Indeed, Canada is follower very next to the United States. Special inventive performance 
can be appreciated by the Nordic countries (Danmark, Finland and Norway) in the second period. 
Spain shows a little increasing inventiveness for the long of the period studied, but still weak until 
now.
6
  Finally, we observe (table 1) that in the last sub-period (2001-2005), the whole countries, 
                                                 
4 We have not included in this estimations Argentina, Brazil, China and Ireland because we have not complete all the statistical data. 
5 We have include, as we specify in the methodology, 4 USPTO patent classes; those belonging to pharmaceutical field and those 
corresponding to biotechnology field due to the proximity in the knowledge production. Between these four classes there are important 
flows of knowledge that are use in pharmaceutical industry. 
6 To compare the level of patenting of industrialized countries we must consider that the propensity to patent for US firms and inventors is much 
higher in their home country. Some other countries like Japan, even if his R&D spending and patenting are high, there are very few new chemical 
entities that can be attributed to this country. 
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with exception of Germany, have decrease this indicator of inventive capacity level. It has to be 
considered the existence of diminishing returns in the inventive activity and the necessity of external 
recharges coming from others fields or progress in the basic sciences. Consequently, investment in 
R&D should increase not only in the pharmaceutical field, but also in scientific fields that permit 
new finds that strengthen inventive activity. Investment intended for scientific programs such as the 
human genome will undoubtedly offer new technological opportunities for the development of new 
medicaments. 
 
Otherwise, the inventive activity of the three developing countries is almost nil in the first 
period, and is expressed in an incipient manner in the second period in Korea and lower in India. 
The differentials between these countries are revealed in the third period, in which South Korea 
takes off in a surprising way, whereas Mexico remains stagnant and India stays marginally. 
 
If we estimate the number of USPTO patents of each country related to the United States, we 
can appreciate the huge differential of this country with all other developed countries and even more 
with the developing countries, including China, Brazil, Argentina and Ireland.
7
 Indeed, on 
comparing the absolute number of patents among these three developing countries the backwardness 
of Mexico can be appreciated, because since the end of the 90’s it has been greatly surpassed by 
South Korea. 
                                                 
7 During the early 90s the numbers of American pharmaceutical patents granted has almost been stagnated and his dynamics growth 
has been recuperated after 1996, even if the new patents do not mean new chemicals entities. It is very probable that the process of 
mergers and acquisitions in this industry has contributed to the slowdown of patents growth of American firms, but in a second time 
(the second half of the 90s) the effort of invention have been increased with a favorable framework of intellectual property laws in his 
country and others countries.                                                                                                                   
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Fig 1 A. Bio-pharmaceutical USPTO patents gaps between industrialized 
countries
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In relation to the pharmaceutical innovation productivity of each, measured by the number 
of patent per employee, United States and Japan show high productivity in the first two sub-periods 
versus to other developed countries. In the third one only the American country keeps the 
leadership, instead Japan lost drastically its productivity level and Canada gains productivity. In 
which concern to European countries, France register a productivity step up in the second sub-period 
and it is maintained in the third one. By its side, Denmark, Finland and Spain increase marginally 
their productivity. Similar performance is that of Korea and in a lower level is India. By the 
contrary, Mexico has a very marginal increase in the second period but it keeps stagnant in the third 
one. 




In comparing the two measures of technological indicators based on patents, the inventive 
capacity level, and the innovation productivity, we admit that there are not so much differences 
between the tendencies. But we observe greater productivity in Canada that innovating success 
performance. Otherwise, Denmark has a mayor performance than productivity.                                                                                                                                                                                                                                                                                                               
 
From the R&D effort come the following observations (see Table 1): 
The levels of intensity of R&D expenditure relative to the GDP of the pharmaceutical 
industry among industrialized countries are more homogeneous. An notable R&D effort is made by 
Japan, in first place, United States, Belgium and Spain. 
                                                                         
The effort on R&D spending in the four developing countries coincides with what is 
expressed in the inventive activity performance, based on patents. Korea has increased the R&D 
effort and India also, but in a lower level. Finally the worst situation is for Mexico who, far from 
having an increase, has an alarming diminution in the spending on R&D in pharmaceutical industry 
and is not associated to the growth rate of GDP. 
 
Table 1. Pharmaceutical technological and innovation indicators average performance  
  Inventive capacity level 
Pharmaceutical innovation 
productivity R&D effort   















States 0.5760 1.2578 0.5474 4.0471 6.9792 5.5451 0.0104 0.2656 0.5735 
Canada 0.5033 1.1530 0.5824 0.7677 0.1316 0.6419 0.0043 0.2089 0.0335 
Japan 7.4717 6.5893 0.0506 7.1281 6.3549 0.5195 0.0063 0.2579 1.8567 
Germany 0.5263 0.5324 0.0541 0.9876 1.0291 1.0343 0.0132 0.2938 0.3042 
France 0.3560 0.4802 0.0453 0.6636 1.0067 0.9659 0.0170 0.2833 0.2886 
United 
Kingdom 0.0253 0.1789 0.0234 0.0073 0.0428 0.0502 0.0168 0.3907 0.4705 
Mexico 0.0054 0.0075 0.0007 0.0043 0.0062 0.0061 0.0034 0.0033 0.0013 
Korea 0.0160 0.3207 0.0695 0.0101 0.2075 0.4556 0.0028 0.1540 0.0874 
India 0.0006 0.0040 0.0015 0.0056 0.0407 0.1487 0.0031 0.0658 0.0727 
Australia 0.1753 0.1418 0.0092 0.2731 0.2298 0.1554 0.0046 0.2656 0.3643 
Belgium 0.0945 0.1032 0.0237 ND 0.1075 0.1248 0.0237 0.2534 0.6344 
Danmark 0.1263 0.5695 0.0621 0.0892 0.2715 0.2400 0.0128 0.3162 0.3413 
Finland 0.1548 0.3327 0.0218 0.2208 0.4237 0.2577 0.0145 0.3626 0.4275 
Netherlands 0.0995 0.1614 0.0132 0.1177 0.1753 0.1331 0.0132 0.2394 0.2737 
Norway 0.1472 0.3760 0.0082 0.0309 0.0534 0.0095 0.0079 0.2499 0.1494 
Spain 0.0619 0.0865 0.0005 0.0626 0.0878 0.0053 0.0038 0.0629 0.8440 
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Spearman variation coeffcient 1980-1990 1991-2000 2001-2005 
Index RI&DF/AI514,424,435,800 0.389286 0.475000 0.060714 
Index R&DEF/GDPPERCNAT  0.264286 0.350000 -0.071429 
Index IA514, 424, 435,800/GDPPERCNAC 0.657143 0.800000 0.532143 
Index IAPT514, 424, 435,800/GDPPERCNAC 0.546429 0.464286 0.367857 
 
The Spearman variation coefficient, suggest a near relationship between patents and R&D. In this 
research there is an interest in determining to what extent these indicators of technological level 
foster the innovation rate, which joint to capital investment (technology transfer) and productivity, 
make it possible to explain the convergent or divergent tendencies at the level of technology, and, 
therefore, the growth of the pharmaceutical industry. 
  
The validation of the patents and the ER&D as an indicator of the results and the input of the 
innovation process, respectively, have been made by means of various empirical studies 
(Schmoockler, 1966; Bound, et. al. 1986). Generally, the results have demonstrated that a 
correlation exists between the number of patents obtained and ER&D. In these studies it was 
detected that the calculation of patents possesses a noise component that is not explained by the 
level of ER&D, but rather by the variations inside the industry and the system of patents. The 
differences in the factors of supply and demand, which indirectly affect the ER&D, also exert an 
influence, and consequently on the level of patents. 
 
The growth rate of ER&D affects the growth rate of patents in the pharmaceutical industry of 
country i in period t in a positive way, that is to say, the calculation is expected to indicate that the 
correlation is positive. The validation of this assumption is shown by doing dispersion diagrams, 
which identify the effects of the R&D growing rhythm on that of the patents in the industrialized 
and developing countries in the pharmaceutical industry for the period studied. 
 
On analyzing these diagrams we observe (see figure 2A and 2 B):  
Firstly, in almost all the industrialized countries the R&D has a positive influence over the 
level of patents except in the case of Spain. In the Spanish case it seems to be linked to the 
heterogeneity of the pharmaceutical firms in this country; there are firms with better performance 
and research capabilities that have started on the path of innovation but still remain a greater extent 
of firms far from of virtuous circle (D’Este, 2003). The United States corroborate his leadership in 
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the pharmaceutical industry at the same time that shows a very strong correlation between R&D and 
patents. In which respect to European countries we observe a homogeneous growing tendency, very 
close to that of Japan, except for the cases of Norway and Belgium where the dynamics in which 
R&D impacts patents has been positive but irregular. It is important to underline the United 
Kingdom case, where the influence of R&D on patents has significance but his innovation path is 







In developing countries two tendencies associated with the dynamics of ER&D of the 
pharmaceutical industry are observed, and they are reflected at the level of patents. On the one hand, 
South Korea with an important exponential growth in ER&D and India as follower in the bloc of 
developing countries, which is, accompanied by a significant growth in patents, especially since the 
90’s. On the other hand, there is Mexico with an erratic performance. Mexico observes a slow 
growth of ER&D in the pharmaceutical industry (and even negative growth for Mexico since 1992) 
and a meager growth in patents (see Figure 1B).  
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Figure 2B. Pharmaceutical industry in developing countries: log of patents versus 
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Technological gaps and convergence in pharmaceutical industry across countries 
 
The aim of this section is to test the unconditional and conditional convergence.  The first 
concept, defined also as -convergence, according to Barro (1984), Baumol (1986), De Long (1988), 
Barro (1991) and Barro and Sal-i- Martin (1992), “applies if a poor economy tends to growth faster 
than a rich one, so that the poor country tends to catch up with the rich one in terms of the level of 
per capita income or product”.
8
 The second concept, the -convergence or conditional convergence 
concerns cross-sectional dispersion and occurs if the dispersion –measured, by the standard deviation 
of the logarithm of per capita income or product across a group of countries or regions- declines over 
the time (Easterlin, 1960; Borts and Stein, 1964; Streisser, 1979; Barro, 1984, Baumol, 1986, 




The -convergence has been tested for developed countries by Baumol (1986), Barro and Sala-i 
Martin (1991), among others. Barro and Sala-i-Martin (1992) developed a model of  convergence 
which supposes that economies with different structure could converge, even the existence of factors 
                                                 
8 R. Barro and X. Sala-i-Martin, 1995: 383. 
9 Cited in Barro and Salai-i-Martin, 1995: 383. 
Paper presented in the VI Globelics Conference, September 22-24 2008, Mexico City 
 
 
that determine the economic steady state of the countries.
10
 This sort of models involves factors 
affecting economic growth. In this research we analyse a sectorial economic growth, where growth 
rate of patenting and research and development could affect the converging or diverging tendencies. 
 
In this case we propose the innovation variable as a conditional factor of pharmaceutical steady 
state differences of each country.  
 
Unconditional convergence ( convergence) 
Following Barrro and  Sala-i-Martin (1991), the  convergence process in the pharmaceutical 
industry could happen when a country has low initial pharmaceutical value added per employee 
(Yf/L) and its growth rate is faster than in a country with a higher value added per employee.
11
 On 
the contrary, the divergence process occurs when the countries with higher initial value added per 
employee grow quicker than those with lower value added per employee. This kind of analysis 
could be applied to patents and R&D expenditure to test the technological convergence. Countries 
with bigger growth rate patents (or R&DE) in the case of initial reduce patents (or R&DE) level in 
relation to those countries with log initial higher patents (or R&DE) but smaller growth rate patents 
(or R&DE), are closing the technological gaps and therefore are in a converging or catching up 
process.  
 
According to our estimations of the linear relation between the average growth rate value 
added per employee (1980 and 2005) and the log initial value added per employee (1980), figure 
1 shows a converging process in most of the cases. Indeed, among the sixteen countries selected, 
the countries with a fewer value added per capita has reached a higher average growth rates, with 
the exception of India. Norway stands up by its log initial low value added but a speedy increase 
rate. 
 
                                                 
10 En México, se realizó un estudio sobre convergencia absoluta y condicional entre los Estados. See Mendoza, E y V. Torres, 
2002. Innovación tecnológica y crecimiento regional en México, 1995 – 2000, Revista Mexicana de Economía y Finanzas, Vol 1, 
No. 3: 187 – 201.  
 
11 In the case of de GDP, Barro and Sala-i-Martin- use the income per capita. In this study, the pharmaceutical valued added per 
employee could be considered as a labor productivity indicator. 
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The whole developed countries, without Norway, have reached an initial value added per 
employee high (specially, Japan) even if their growth rate is not as faster as that one from the 
United States and Belgium, therefore the dispersion among these countries is reduced. Japan, 
Spain, Germany and Australia show bigger initial labor productivity but they grow slowly than 
the others. The speed growth tendency from the United States confirms its international 
pharmaceutical leadership, followed by Japan and the European countries, associated to 
technological performance (patents and R&D). Particular importance have, the Scandinavian 
countries converging process (Denmark and Finland) which have converged to other European 
countries (Germany, France, Royal Kingdom). 
 
In which concern to developing countries, we observe two tendencies. The first one is a 
catching up process from Korea and Mexico in relation to the levels of developed countries and, 
the other one, is a diverging process from India. Korea and Mexico have reached a higher growth 
rate than the whole countries selected. Nevertheless, the nature of this converging tendency is 
associated to different kind of factors. By one hand, the Mexican huge growth rate could be 
explained because of the pharmaceutical multinationals market expansion in this country, in a 
globalization process framework, specially, with the NAFTA agreement. The pharmaceutical 
market (by its sale volume) in Mexico has register high growth rates (more than 10% in some 
years) and it is considered as the top ten world markets joint to an important export activity; 
meanwhile the level of imports has increasing faster and, therefore, this country has a negative 
trade balance. This fact reveals the internal weakness of the pharmaceutical industry linked to a 
technological an innovation performance, which is going to be analized later. By the other, 
Korea, a recent industrialized country, has been recognized by its strong R&D and innovation 
effort, so it is easy to explain that the higher growth rate in pharmaceutical productivity is 
associated to the technological catching up. Finally, the case of India is surprising, because this 
Asian country has increasing its imitating capabilities to produce an important level of generics 
drugs in last two decades and has become one of the main generic export countries. But it is 
necessary to take into account that the Indian market is not so large because the low income per 
capita and also there some population who refuse to take therapeutic treatments link to certain 
religious ideas; the generic drugs prices are significant lower than those patent drugs, therefore 
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the sale volume is relatively low in comparison to those countries like Mexico where the patent 
drugs segment is more important. 
 
 
Figure 3. Pharmaceutical  labor productivity convergence across countries, 1980-2005 
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Considering the technological gaps focus, we wonder if the pharmaceutical labor 
productivity converging tendencies of the developing countries compared to the industrialized 
countries are explained with rates of economic growth higher than those registered by 
industrialized countries, linked to an important development of technological and institutional 
capacities. So, we proceed to test the  convergence hypothesis in the case of bio-pharmaceutical 
patents (identified as an innovation indicator) by considering the linear relation between the 
growth rate of patents and the log of initial patents. Figure 2 shows how there are countries with a 
low initial level of patents but their patents growth is faster than others who have a bigger initial 
level of patents.  
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Figure 4. Bio-pharmaceutical patens convergence across countries, 1980-2005


















































Conditional convergence ( convergence) 
 
By estimating the standard deviation of the logarithm of the value added per employee or value 
added across the countries selected we can test if the dispersion across the group of these 
countries declines over the time; in that case we are in  convergence. The innovation variables 
effects (R&D stock and patents) could have a decisive influence (Barro y Sala-i-Martin, 1991). 
To test the innovation impact in converging process hypothesis in pharmaceutical industry we 
develop the next model based on the Fagerberg (1989) proposal. If there is a convergence 
tendency, the explanatory variables coefficients are expected to be negatives.  
 
The differentials in the technological level of the pharmaceutical industry between 
industrialized and developing countries cause the need for other explanatory variables associated 
with the specific conditions of each country. In this context the explanatory variables for the 
pharmaceutical technological gaps or value added per employee converging tendencies are 
considered as a function of the value added per employee, the availability of knowledge, and the 
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efforts to innovate. Therefore, three variables are included: i) pharmaceutical value added per 
employee, with a lag period (VAf/Lft-1); ii) the previous year’s patents (PATF t-1); and iv) the 
stock of research and development spending of the industry (RDSTOCKFit). 
 
According to convergence model we assume that value added per employee (VAf/Lf) 
growth rates are explained by the previous year’s level (VAf/Lft-1), moreover, we assume that a 
country with stable economic growth (high GDP per capita) will have a greater responsibility to 
obtain positive results from innovational activity
12
; in other words, we assume the gap is going to 
increase. 
 
 As has been verified in the previous models, the new knowledge, reflected in the 
previous year’s patents (technological opportunity), is an input for the innovations of the present 
period (PATF). Lastly, the STOCKIDF is the principal input for innovation
13
 and reflects the 
efforts of the industry to stay in the marketplace.  
 
Based on the preceding, the model proposed for the study of technological gaps or  
convergence in the pharmaceutical industry for developing and developed countries is the following: 
TVAF /LFt = f (VAF/LFt-1, PATFt-1, STOCKIDFt) 
The model is analyzed by means of the econometric calculation of the panel of data using 
the following equation: 
TVAF /LFit = c(1) + c(2) * LOG(VAF/LF it-1 )+ c(3) * LOG(PATF i,t-1 ) +  c(4) * LOG(STOCKIDIF it ) + eit       {1} 
where:  
 
TVAF/LF it =  matrix, which represents the pharmaceutical value added per employee growth rate of 
country i in period t.  
LOG(VAF/LF i-1t )= matrix of the log10 of pharmaceutical value added per employee of country i in millions 
of US dollars at 1990 prices in period t.  
LOG(PAT i,t-1  )  = matrix of the log10 of patents in the pharmaceutical industry of 
countries i obtained from the USPTO (classes 514 or 424 or 435 y 800) in period t minus 
1. 
LOG(STOCKID it ) = matrix of the log10 of ER&D stock of countries i in millions of US 
dollars at 1990 prices in period t.  
e it     = matrix of the errors of countries i in period t. 
 
                                                 
12 This idea is known as Schmookler’s hypothesis. See Schmookler, J., Invention and Economic Growth, Harvard University Press, 1966,  pp. 28-30.  
13 This happens especially in the pharmaceutical industry. 





The three variables are positive and significant, which means, that the pharmaceutical 
value added per employee in the previous period (t = 1.1429), the patents granted in the previos 
period (t = -1.3321) and R&D stock  (t = 1.1390) have an impact on the value added par 
employee growth rate, and therefore, they contribute to reduce or increase the technological gap 
and so, the converge or divergence.  
 
Indeed, the results show that VAF/LF and the R&D, both in the previous period, 
contribute to increase the technological gap and therefore to the diverging tendency. Both 
coefficient signs are positives (1.6514 and 1.2186), which suggest that countries with lower level 
in both variables will grow less quick than countries with higher initial levels. That mean, that the 
innovation variable R&D stock is significant in the diverging economic process. The countries 
with more R&D expenditure are those ones with more value added par employee, and this favor 
to extend the pharmaceutical gap.  
 
By the opposite side, negative sign of the patents variable (-1.369970) reveal that more 
patents do not necessary become in bigger growth rates. Even if the patents gives monopolist 
commercial protection, there are important knowledge spillovers associated to the patent 
disclosure, which the technological follower countries can take advantage of. Figure 2 showed 
patent converging tendency.  
 
 
Table 2. Dependent variable: Value added par employee growth rate 
TVAF/LF it 
Method: Pooled Least Squares 
Period = 1981 – 2005 = 25 observations. Whole total : 279 
Include 16 countries 
     
     
Variable Coefficient Std. Error t-Statistic Prob.   
     
     
LOG(VAF/LF i-1t ) 1.651401 1.444806 1.142991 0.2540 
 
LOG(PAT i,t-1  ) 
  -1.369970 1.028376 -1.332168 0.1839 
LOG(STOCKID it ) 1.218606 1.069861 1.139033 0.2557 
     
     
Durbin-Watson stat 2.374589     F-statistic -1.717319 
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      Prob(F-statistic) 1.000000 
     
     
 
Nevertheless the value added per employee growth rates (Figura 1) suggest converging 
process in almost all countries, with exception of India and Norway, it is suitable to consider the 
differences across countries according to  convergence. However, the fact cannot be ignored 
that in the panel a group of economies with heterogeneous pharmaceutical industries is being 
considered, especially among developing and developed countries.  
 
The differences detected in the dynamics of patents in the pharmaceutical industry of 
developed and developing countries during the period analyzed are convincingly explained by the 
differences in the efforts at innovation (ER&D stock) and the taking advantage of technological 
opportunities (the previous year’s patents). So, whereas there is a high level of innovation in 
developed countries, the developing countries are associated with a lack of substantial 
technological innovations. 
 
Nevertheless, it is indispensable to consider the differences in development between the 
industrialized countries, with a high technological level, and the developing countries that depend 
basically on the transfer of technology from outside and their ability to assimilate it. Therefore, it is 
convenient to evaluate the model in blocks, that is to say, separating developing and developed 
countries. 
 
Technological Gaps in the Pharmaceutical Industry of Developed Countries 
 
Table 3. Depent variable: Pharmaceutical value added growth rate per employee 
TVAF/LF it 
Method: Pooled Least Squares 
Period = 1981 – 2005 = 25 observaciones. Whole total: 249 
Include 13 countries   
     
     
Variable Coefficient Std. Error t-Statistic Prob.   
     
     
LOG(VAF/LF i-1t ) -0.553626 1.985869 -0.278783 0.7806 
 
LOG(PAT i,t-1  ) 
  -1.009253 1.066952 -0.945922 0.3451 
LOG(STOCKID it ) 2.219898 1.256397 1.766876 0.0785 
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Durbin-Watson stat 2.362457     F-statistic -1.334792  
      Prob(F-statistic) 1.000000 
 
 
In the bloc of the industrialized countries at a panel level, we observe that the innovation 
variables affect positively the technological development, but in a way more than proportional 
[STOCKIGt (2.219898)]. In fact, R&DE is the sole significant statistical variable to explain the 
VAF/LF growth rates differentials across countries (t=1.766876). Thus, the results show that the 
initial pharmaceutical value added par employee and the bio-pharma patents level are not statistical 
significant to contribute the gap among the countries (t =-0.278783 y t=-0.945922). This gap, in 
other words, growth rates divergences, is explained by the R&DE, thus, the countries with higher 
initial R&D effort (R&DE) could reach bigger growth rates. This fact looks to confirm, that in the 
innovation process, R&DE is an ex – ante condition.  
 
Technological Gaps in the Pharmaceutical Industry of Developing Countries 
 
When the model at a panel level is calculated for the same period but only for the 
developing countries (Mexico, India, Korea) the results are substantially different. The innovation 
variables (patents and R&D expenditures), are not statistical significant to explain the 
pharmaceutical value added par employee (t= 0.0342 y t= -0.0272). This is probably due to the fact 
that for these countries, the imitation strategy, by means of the technology transfer, has been 
important in their take-off towards innovation.  The divergence tendency among these three 
countries is explained by the initial VAF (t=1.580605). In the Mexican case, even if the VAF 
average growth rate is large, (1980-2005), the R&DE and the patents level have an erratic 
performance. 
Table 4. Dependent variable: Value added par employee growth rate 
TVAF/LF it 
Method: Pooled Least Squares 
Period = 1981 – 2005 = 25 observations. Whole total: 249 
Include 13 countries 
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Variable Coefficient Std. Error t-Statistic Prob.   
     
     
LOG(VAF/LF i-1t ) 3.613289 2.286017 1.580605 0.1256 
 
LOG(PAT i,t-1  ) 
  0.190695 5.568419 0.034246 0.9729 
LOG(STOCKID it ) -0.115349 4.239178 -0.027210 0.9785 
     
     
Durbin-Watson stat 2.446870     F-statistic 0.806043 
      Prob(F-statistic) 0.457080 
     
     
 
 
The results of developing country at panel level give different paths evidence among 
them, explained by their particular technological development, including the ability to learn and 
absorb foreign technology. By one hand, Korea look for diminishing the gap with respect to the 
industrialized countries.  By the other hand, the countries that far from having convergence tendency 
they show an erratic performance, widening the technological gap: Mexico.  
 
Many studies have identified the wide expenditure on education, on ER&D, on 
transferring technology as the main sources of Korean economy’s growth (See Amsdem, 1987; 
World Bank, 1993). Nevertheless the strength of the intellectual property rights (IPR) in 
pharmaceutical industry was too early (1987) -because of the pressure of the Unites States- when 
Korea “was incapable of developing new internationally marketable drugs” (La Croix & Kawaura, 
1996). Therefore, even if Korea registered wealth losses, this Asiatic country has started since then a 
path of convergence because of his technological capabilities build in the previous years. An 
opposite strategy was followed by India, which has retarded the adoption of stronger IPR and they 
continued with intensive imitation in a protection environment for the domestics firms (Lanjow, 
2000). Finally, Mexico was pressured too to strengthen its IPR with the negotiations of North –
America Free Trade Agreement (NAFTA). Mexico adopted the Trips in 1991 even if the domestic 
firms expected them until 1997, ten years after the entrance to GATT. The absence of a virtuous 
circle in the Mexican pharmaceutical industry could be understood because of the weak investment 
on R&D (See Guzmán & Brown, 2003). But also because of the kind of entrepreneurs which have 
grown in protectionism environment during several decades and they used to have his market place 
in the wealth public sector in generics drugs with generous profits without building necessarily 
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technological capabilities (Guzmán & Zúñiga, 2004). So, Mexico has invested in the formation of 
scientists (physicians, biologists, chemical) with international scientific production but it has not 
been capitalized by the industry to generate synergies. 
 
Conclusions 
In this empirical investigation the hypothesis that the feedback that is established between 
R&D and patents propels the innovative capacities of industrialized countries in pharmaceutical 
industry is corroborated.  
The technological and innovational leadership of the United States here is conclusive. 
Nevertheless, other countries, in particular Japan, have made a great spending effort on R&D, 
surpassing the growth rates of this indicator and of patents of the leading country, and with this they 
are starting out on the road to convergence. Even the technological homogeneity of the European 
countries (except Spain), Japan and Canada, we distinguish especially four of them that have 
developed a convergence path: Japan, France, Germany and the United Kingdom. But there are also 
the Nordic countries and Canada with a convergence tendency at a lower level. 
 
The gaps are even greater if developing countries are considered, especially when the 
R&D and patent levels are meager compared to the industrialized countries, and even more when we 
compared to the leading country. 
 
In order to explain the convergence or divergence growth patents tendency between 
countries we find that at a panel level the main factors are: the availability of knowledge and the 
efforts to innovate. Given the technological backwardness from the developing countries, the 
empirical evidence of panel by bloc and countries shows different paths of growth and innovation.    
In the bloc of the industrialized countries at a panel level their innovation path is 
associated only by the innovation variables (the previous year's patent and the stock on R&D). By 
considering each country as a whole of the industrialized countries, the United States confirms its 
position as the technological leader in the pharmaceutical industry, link to their high level on R&D 
expenditures and the stock on patents. Without the United States the results are maintained. But at a 
country level, we find, by one hand, that only for Japan, France, Germany and the United Kingdom 
the innovation variables rested significant. By the other hand, the industrialized countries followers 
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still explain their technological development of the pharmaceutical industry not only by innovation 
variables but by one imitation variable too, GDP per capita (Finland, Spain, Norway, Australia, 
Belgium, Denmark, Netherlands and Canada). Only Spain shows impact from the imitation variable 
(GDP per capita).  
Nevertheless, by considering the developing countries panel we find that technological 
gap, measured by patents level, is explained by the gross fixed investment, the previous year’s 
patent and the stock on R&D.  In observing the differences of the path the developing countries 
selected we find, by one hand, these which look for diminishing the gap with respect to the 
industrialized countries: India and Korea (explained by the GDP per capita, the stock on R&D and 
the previous year's patents). By the other hand, the countries that far from having convergence 
tendency they show an erratic performance, widening the technological gap: Mexico. Even if South 
Korea remains lagged with respect to level of the developed countries, his growing and innovation 
path tends to be systematic and increasing. India follows to strengthen the imitation’s way 
meanwhile Mexico is stagnated. The differences between developing countries could be understood 
in considering the way in which each country builds its technological capabilities in a virtuous circle 
between capital investment and innovation.  
 
METHODOLOGY 
Data and Sources 
The ER&D level was calculated using the method of perpetual inventories (Mohen, 1990):  
STOCKID = ∑
3
ζ=0   δ
ζ 
(ER&Di,t- ζ ) 
Where ER&Di is the research and development expenditure of country i in period t, in millions of US dollars, 
deflated to 1990 prices. The number of regressions applied is 3 (ζ = 0, 1,2,3)
14
. According to Griliches (1979) 
the rate of obsolescence is assumed to be 15% annually (δ). For the purpose of this calculation it should be 
taken into account that the level of stock on R&D implies that one observation were lost (1980), thereby 
reducing the size of the sample from 25 to 22 observations. 
  One of the main problems is that an aggregation of patents, as well as the other measures of 
technological innovation, includes items of very heterogeneous value: to add up patents implies that 
inventions with different economic and technological significance are merged
15
. By this reason, patents, even 
if it is a good raw ingredient for quantitative analyses is not as the same for qualitative analyses. In this study 
                                                 
14 This assumption being taken from the work of Grilliches (1979) in which it is argued that the effects of ER&D persist for approximately 3 to 4 
years. 
15 Archibugi (1992), p. 359 
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we have chosen the idea of common market to compare the patenting activity of all the countries selected 
with the patents granted by the US patent office. Finally, all countries are submitted in the US patent office at 
the same rules. By considering that the propensity to patent of the United States is higher in their home 
country we do not compare this indicator with the rest of the countries.
16
 The annual information on patents 
granted to each country in the United States was obtained from the database of the United States Patent and 
Trademark Office (USPTO). The search was carried out by taking the USPTO classes linked to 
pharmaceutical industry: those corresponding to drugs: 514 (Medication and compounds for the treatment of 
biological and corporal infections) and 424 (Drugs, bioafecting and body treating composition) and those 
belonging to biotechnology: 435 (Chemistry: molecular and microbiology and 800 (Multicelular living 
organisms and unmodified parts thereof and related processes). The USPTO is consulted according to the 
volume of systematized information it has, this being linked to the importance that the United States has in 
technological competition. 
 
 The data for the pharmaceutical value added 
17
 and the gross fixed investment of each country, in its 
national currency come from the Stan database of the OCDE for various years, with the exception of India. For 
this country the national Statistical Yearbook of that country was consulted. The  pharmaceutical value added 
and gross fixed investment at current prices was deflated in 1990 prices and was converted to U.S. dollars by 
using the purchaching power parity (PPP) 1990 relative to USA. The population of each country was obtained 
from the Annual Population Statistics of the United Nations for various years. The national per capita GDP 
was calculated based on the GDP and the population of each country. 
In order to analyze the pharmaceutical technological gaps and converging or diverging trends 
between countries we consider the average performance of three technological indicators in three different 
periods. The first one, is the level of pharmaceutical inventive capacity, which is calculated based on the 
number of pharmaceutical patents (classes 514, 424, 435 and 800) weighted by the size of each country, 




                                                 
16 In so far as patents are concerned, some studies of patenting among countries indicate that the different regulations make comparison difficult, so 
they propose consulting a common (foreign) market such as the USPTO (Soete, 1981). Other studies prefer to consult non-resident patents in the 
global market registered with the Intellectual Property Organization (WIPO), because in this organization the patent concessions of country x are 
tabulated for all countries except country x. This external patent level can be correlated with the country’s level of exports (Fagerberg, 1987).  
 
17 Value added represents the contribution of each industry to GDP. 
18 The patents per hundred thousand inhabitants, has been identified as the inventive capacity of the country. The positive export 
coefficient could be linked to an innovating success performance. 
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The second indicator is the level of pharmaceutical innovation productivity; it was estimated based 
on the pharmaceutical patents (classes 514, 424, 435 and 800) per number of employees engaged in 
pharmaceutical industry of each country.  
The third indicator is the pharmaceutical R&D effort. It was calculated by using pharmaceutical R&D 
expenditure as a percentage of the pharmaceutical value added.   
Also, the relationship between R&D and patents was calculated.  The relation of each indicator to the 
level of economic development (expressed in per capita GDP at 1990 prices), was estimated through 
correlation’s Spearman’s coefficient. The value of each interval was obtained by calculating the arithmetical 
average. During the periods selected, the Trade Related Aspects of Intellectual Property Rigths (Trips) have 
been adopted in different years by the countries. 
Nevertheless, the average performance of the three technological indicators only show the innovation 
dynamics differs and trends, but the overall countries technological gap related to the technological leader 
(United States) is displayed by estimating a coeficient of variation (standard deviation mean).  
Afterwards we proceed to analyze the technological dynamics at the country and country panel level. 
Firstly, the impact that the ER&D has at the patent level in each country can be seen in plots of the log of 
patents versus log of ER&D (correlogram). Finally, to test the -convergence, we have considered the 
Barro’s model. The  -convergence is measured the by the innovation level (patents), as a function of the 
previous year’s patents VAf-1/L, the availability of knowledge (the previous year’s patents), and the R&D 
efforts to innovate (the stock of ER&D) and with that the position that the pharmaceutical industry of each 
country is determined, according to its technological performance. 
A serious limitation for the study is the size of the series available (25 observations for each country), 
which reduces the possibility of having a stable economic calculation. It would be better to have a sample of 
at least 60 data. 
The results obtained from the proposed models present: i) the size of the sample (n)
19
; ii) the parameter’s 
estimated value, and between parentheses the standard deviation (SD); iii) the value of the statistics: F, and 




a are omitted because they 






                                                 
19 A small sample (less than 60 observations) provides unstable calculations: the presence of autocorrelation and the t statistic are 
very small. 
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